Yao, Wei
Cao, Qianqian
Luo, Shilin
He, Lujuan
Yang, Chun http://orcid.org/0000-0003-1540-4385
Chen, Jiaxu http://orcid.org/0000-0002-5570-6233
Qi, Qi http://orcid.org/0000-0003-4460-0713
Hashimoto, Kenji http://orcid.org/0000-0002-8892-0439
Zhang, Ji-chun http://orcid.org/0000-0001-6035-6867
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (21H02846, 24116006)
National Natural Science Foundation of China (81973341)
Article History
Received: 16 August 2021
Revised: 20 October 2021
Accepted: 22 October 2021
First Online: 24 November 2021
Change Date: 8 December 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41380-021-01417-2
Competing interests
: KH is the inventor of filed patent applications on “The use of (<i>R</i>)-ketamine in the treatment of psychiatric diseases”, “(<i>S</i>)-norketamine and salt thereof as pharmaceutical”, “(<i>R</i>)-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder”, “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases”, and “(<i>R</i>)-ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder” by the Chiba University. KH also declares that he has received research support and consultant from Dainippon Sumitomo, Otsuka, Taisho, and Perception Neuroscience. Other authors declare no competing interests.